The development of molecular testing for identifying somatic mutations and immune checkpoint biomarkers has directed treatment towards personalized medicine for patients with non-small cell lung cancer. The choice of molecular testing in a clinical setting is influenced by cost, expertise in the technology, instrumentation setup and sample type availability. The molecular techniques described in this review include immunohistochemistry (IHC), fluorescent in situ hybridization, direct sequencing, real-time polymerase chain reaction (PCR), denaturing high-performance liquid chromatography, matrix-assisted laser desorption/ionization time of flight mass spectrometry and next-generation sequencing (NGS). IHC is routinely used in clinical practice for the classification, differentiation, histology and identification of targetable alterations of epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) and programmed death ligand-1 (PD-L1). Recently, the PD-L1 pathway was identified as being exploited by tumour cells, allowing immune resistance and tumour evasion. The development of immune checkpoint inhibitors as treatment for tumours expressing checkpoints has highlighted the need for standardized IHC assays to inform treatment decisions for patients. Direct sequencing was historically the gold standard for mutation testing for EGFR, KRAS (Kirsten rat sarcoma viral oncogene homologue) and BRAF (vRaf murine sarcoma viral oncogene homologue B1) requiring a high ratio of tumour to normal cells, but this has been superseded by more sensitive methods. NGS is a new emerging technique, which allows highthroughput coverage of frequently mutated genes, including less common BRAF and MET mutations and alterations in tumour suppressor genes. When an NGS platform is unavailable, PCR-based technologies offer an efficient and cost-effective single gene test to guide patient treatment. This article will review these techniques and discuss the future of molecular platforms underpinning clinical management decisions.
INTRODUCTION
Together with histology, information about molecular alterations at the protein and genetic level is considered crucial to guide treatment selection in patients with advanced stage non-small cell lung cancer (NSCLC). 1 Key molecular aberrations identified in NSCLC include mutations in the epidermal growth factor receptor (EGFR), KRAS (Kirsten rat sarcoma viral oncogene homologue) and BRAF (v-Raf murine sarcoma viral oncogene homologue B1) genes, translocation in genes such as anaplastic lymphoma kinase (ALK), ROS1 (c-ros oncogene 1), RET (rearranged during transfection), NTRK (neurotropic tropomyosin receptor kinase) and gene amplification in fibroblast growth factor receptor (FGFR), MET and human epidermal growth factor-2 (HER-2) ( Table 1 ). Many of these molecular alterations have been exploited as predictive biomarkers to select patients for molecularly targeted therapy, resulting in improved outcomes in molecularly selected patients treated with targeted therapy. 2, 17 The identification of the programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) pathway as a key factor by which tumours can evade the host immune system has led to the development of immune checkpoint inhibitors. 18 As the PD-1/PD-L1 pathway is implicated in immune escape in NSCLC, PD-L1 expression detected with immunohistochemistry (IHC) has been used as a predictive biomarker to identify patients who might benefit from certain PD-1/PD-L1 inhibitors.
Given the importance of molecular alterations described above, the detection of predictive biomarkers in blood or pathological samples is now routinely performed to guide clinical care in patients with NSCLC. Techniques used include IHC, fluorescent in situ hybridization (FISH), direct sequencing, real-time polymerase chain reaction (PCR), denaturing highperformance liquid chromatography (DHPLC), matrixassisted laser desorption/ionization time of flight (MALDI-TOF) mass spectrometry and next-generation sequencing (NGS) ( Table 2 ). This review article will summarize the current state of molecular methods used for the management of lung cancer.
IMMUNOHISTOCHEMISTRY
Diagnostic IHC is widely used for the classification of primary and metastatic tumours. 19 IHC involves the localization of specific antigens in tissues or cells based on antigen-antibody (Ab) recognition. The majority of NSCLC cases can be subclassified based on histomorphological examination using haematoxylin and eosin (HE)-stained slides but in cases of poorly differentiated carcinomas, specialized IHC staining of the tumour is necessary for the diagnosis and determination of tumour subtype.
In routine clinical practice, the most commonly used IHC markers for the classification of NSCLC are TTF-1 (thyroid transcription factor-1), Napsin A, CK5/6, P63 and P40. [20] [21] [22] The most useful IHC Ab for the identification of glandular differentiation in adenocarcinoma are TTF-1 and Napsin A. TTF-1 has a sensitivity of 75-80% for lung adenocarcinoma 23 and is also expressed in thyroid tissue and thyroid tumours, as well as in neuroendocrine tumours (small cell lung cancer and carcinoid tumours). In addition, Napsin A is also a marker for lung adenocarcinoma. 23 The IHC markers for squamous cell carcinoma include the proteins P40 and P63. The sensitivity and specificity of P40 have been reported to be 100% and 98-100%, respectively, in identifying squamous cell cancers in surgically resected specimens. 23 Novel Ab against the two major EGFR mutations have been developed: SP111, which is specific for the E746-A750 deletion in exon 19; and SP125, which is specific for the L858R mutation. 24 Recently, IHC has also shown itself to be an effective screening strategy for detecting ALK gene translocations in NSCLC. The Food and Drug Administration (FDA)-approved IHC (ALK (D5F3) CDx assay) can be used as a stand-alone test, although secondary confirmation is encouraged. 25 To enrich for patients suitable for immune checkpoint inhibitors, PD-L1 expression with IHC has been used as a predictive biomarker. Multiple PD-L1 assays have been utilized for different PD-1/PD-L1 inhibitors. 26 The recommended in vitro diagnostic (IVD) assay for pembrolizumab and nivolumab is the 22C3 Ab and 28-8 clone, respectively, both using the Dako Link 48 autostainer, whereas for atezolizumab, both tumour and immune cell PD-L1 expression are assessed using the Ab clone SP142 (Ventana). With durvalumab, the SP263 Ab clone (Ventana) has been used for PD-L1 detection (Table 3) . 27 Of the four IVD assays available, the Dako PD-L1 IHC 22C3 pharmDx assay has been approved by the FDA as a companion diagnostic assay for use with pembrolizumab. 28 In contrast, the FDA has approved the PD-L1 28-8 pharmDx and SP142 (Ventana) as a complementary diagnostic for use with nivolumab in non-squamous NSCLC and atezolizumab in NSCLC, respectively. Companion diagnostics is a class of IVD that is required for the safe and effective use of a corresponding product, whereas complementary diagnostics, a new regulatory category created by the FDA, are not required for receiving treatment but provide additional information which might be useful to guide treatment decision. 28 The development of a multitude of PD-L1 IHC assays by pharmaceutical companies has created challenges as these assays used different IHC Ab clones, different staining protocols and platforms, different scoring systems and different cut-offs defining positivity (Table 3) . 28 To overcome the complexity of PD-L1 testing, multiple groups have compared the various PD-L1 assays. A high concordance for tumour PD-L1 expression was observed with 22C3, 28-8 and SP263 assays, whereas weaker staining was seen with the SP142 assay. 29, 30 The clinician would be well served to refer to their local thoracic pathologist for advice, as IHC is an evolving art with non-standardized Ab, alternative clones for the same Ab with choice dependent on the level of healthcare resourcing and local regulatory landscape. A detailed review of the literature on challenges and interpretation of PD-L1 expression by PD-L1 has been addressed elsewhere.
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FLUORESCENCE IN SITU HYBRIDIZATION
FISH is a common technique for the detection of gene rearrangements, regional chromosomal deletions or amplifications, and numerical chromosomal abnormalities. It utilizes fluorescently labelled DNA probes that bind to homologous chromosomal regions and can assay interphase nuclei found in routine formalin-fixed paraffin-embedded (FFPE) sections of lung cancer tissue. 19 The detection of a numerical chromosome changes and regions of gene amplification or deletion typically uses a single probe and one-colour FISH. The FISH assay for chromosomal translocations may use two strategies. One is a single break-apart probe design, in which a single probe that spans the gene of interest is used and will demonstrate a split signal in the presence of a translocation. This approach detects only a specific type of rearrangement between a defined pair of partner genes. 19 The second method uses a fusion probe design, labelled with two different fluorochromes. Chromosomal rearrangements will manifest as a pair of fused signals (Fig. 1) . Examples of the common and important translocations in NSCLC include the ALK gene and ROS1 gene fusions ( Table 1) . The most common fusion partner in ALK-rearranged NSCLC is echinoderm microtubule-associated proteinlike 4 (EML-4). Several different ROS1 gene rearrangements have been described in NSCLC, including SLC34A2-ROS1, CD74-ROS1, EZR-ROS1, TPM3-ROS1 and SDC4-ROS1 32 These gene fusions are therapeutically significant in patients with advanced NSCLC as effective targeted agents are available ( Table 1) .
The advantage of the break apart is its ability to detect all possible translocations involving a particular gene, such as all types of exon 20 breakpoint translocations of the ALK gene in NSCLC but it cannot identify the fusion partner. As a dual fusion probe design will only detect a translocation of ALK or ROS1 to a specific partner, it would not be cost effective or permissible strategy to perform multiple dual fusion FISH probes given the vast numbers of known and yet unknown partner genes, and risk exhaustion of limited biopsy material in order to identify the fusion partner.
DIRECT SEQUENCING
First introduced in 1975, direct sequencing has been a powerful tool in the discovery of key somatic mutations in the cancer genome. 33 This method permits the screening for all mutated base pairs, including small insertions and deletions and has been one of the most well-established and widely used methods used to identify clinically relevant mutations in oncogenes including EGFR, KRAS, BRAF and NRAS (neuroblastoma ras viral oncogene homologue). 34 In practice, direct sequencing is a relatively inexpensive method, and can be easily automated for highthroughput sequencing. 35 However, its clinical utility is limited due to the requirement for specimens with a high ratio of tumour to normal cells. Samples with <20% of mutant allele frequency (corresponding to a minimum tumour cell content of 40% assuming complete heterozygosity) may be considered inadequate for testing or risk a false positive result. 36, 37 The ongoing improvement in NGS technologies and their capacity for detecting low-frequency variants in small diagnostic samples means that direct sequencing is now considered inadequate for routine testing. Direct sequencing is therefore limited to samples with a high proportion of tumour DNA or as a secondary validation method. 25 
REAL-TIME PCR FOR TUMOUR DNA
To overcome challenges associated with allelic dilution in low tumour cell content samples such as plasma, cytological specimens and small biopsies, various quantitative real-time PCR-based methods (Fig. 2 , Table 4 ) have been developed to enable the efficient amplification of the mutant allele among a large background of wild-type (WT) DNA. These methods can apply to the detection of single or multinucleotide variants, including insertions and deletions in EGFR, KRAS and BRAF.
MUTANT-ENRICHED PCR
In mutant-enriched PCR (ME-PCR), the sensitivity of the assay to detect a single mutant sequence among a large background of WT genes is achieved through two rounds of PCR with intermittent restriction digestion to selectively eliminate WT sequence. 56 This method is more sensitive than direct sequencing in the detection of EGFR mutations in clinical specimens including pleural effusions, biopsy and surgically resected tissue. 38, 39, 56 However, ME-PCR has been shown to be less sensitive (36-78%) compared to other mutant enrichment techniques. 38, 57 False positives can occur if a critical number of cycles is exceeded in the second round of PCR, which may induce replication errors and the loss of the WT restriction site. 56 
PNA-LNA PCR CLAMP
The peptide nucleic acid-locked nucleic acid PCR (PNA-LNA PCR) clamp technology utilizes the superior affinity and stability of PNA and LNA oligomer primers for complementary DNA binding, resulting in the enhancement of mutant allele amplification and suppression of WT amplification. PNA clamping is more sensitive than direct sequencing for the detection of EGFR and KRAS mutations in low tumour content samples. 40, 58 Compared with digital PCR or NGS methods, the PNA clamp may be a more cost effective and readily available technology for both tissue and plasma testing where targeted testing is required. ARMS, amplification refractory mutation system; BEAMing, beads, emulsions, amplification, magnetics; BRAF, v-Raf murine sarcoma viral oncogene homologue B1; ctDNA, circulating tumour DNA; ddPCR, digital droplet PCR; DHPLC, denaturing high-performance liquid chromatography; EGFR, epidermal growth factor receptor; FDA, Food and Drug Administration; KRAS, Kirsten rat sarcoma viral oncogene homologue; MALDI-TOF, matrix-assisted laser desorption/ionization time of flight; NGS, next-generation sequencing; PNA-LNA, peptide nucleic acid-locked nucleic acid; PCR, polymerase chain reaction.
SCORPION ARMS
The amplification refractory mutation system (ARMS) uses modified primers with allelic specificity to the mutant sequence, but mismatched to the WT sequence, resulting in the enrichment of mutant alleles. 42 This method can be easily multiplexed, but is limited to detecting known mutant variants only. ARMS-PCR is more sensitive than direct sequencing in detecting EGFR mutations in samples with low tumour content 43 including pleural effusion samples. 59 The Scorpion ARMS technology is the basis of many commercially available diagnostic tests (Table 4) .
DIGITAL DROPLET PCR
Digital droplet PCR (ddPCR) is a highly sensitive method used for many clinical applications, due to its precision and sensitivity for variant quantification at a single-molecule level down to 0.01%. 44, 45 Compared to quantitative PCR where a single sample is measured relative to a reference, ddPCR partitions samples intõ 20 000 nanolitre-sized end-point PCR (Fig. 2) . Each independent amplification event is measured and assigned as either positive or negative for the target of interest. Using Poisson statistics, a digital readout of the absolute concentration of the DNA target is determined without a standard curve and independent of reaction efficiency. Sample partitioning effectively increases the mutant concentration relative to the WT background and enhances the specificity for detecting the target template. 44 The sensitivity for the detection of sensitizing EGFR mutations is 0.04%. 46 ddPCR proves difficult to be multiplexed; however, its sensitivity supports its suitability for a broad range of clinical samples of low tumour DNA content. 47 
BEAMING
BEAMing is another digital targeted method, based on its four principle components: beads, emulsions, amplification and magnetics. Thousands of microemulsions containing a single DNA template, primer-bound bead and PCR components are subjected to conventional PCR cycling to create thousands of bead-bound DNA molecules representative of the original template. The emulsions are subsequently amplified, magnetically purified and hybridized to fluorescent variant-specific probes, and mutant DNA molecules are measured with flow cytometry. 48 A comparison analysis in cell-free DNA (cfDNA) found BEAMing technology to demonstrate sensitivity of 82-86% for sensitizing EGFR mutations and 81% for EGFR T790M mutations. 49 
REAL-TIME PCR ANALYSIS OF CTDNA
Tumour heterogeneity and the practical limitations of tissue biopsies for molecular testing may be overcome by the analysis of circulating tumour DNA (ctDNA) present in blood. Known commonly as a 'liquid biopsy', analysis of ctDNA has gained traction in both the research and clinical sphere for diagnosis, molecular profiling and longitudinal monitoring of therapeutic response. Due to a relatively low prevalence of mutant ctDNA (<0.1%) diluted in a background of both germline and non-mutant cfDNA, 60 highly sensitive PCRbased methods such as ddPCR, BEAMing, ARMS-PCR and PNA-LNA PCR clamping have been used in many studies. 44, 61 Measuring the levels of mutant allele burden in ctDNA at baseline have been shown to have predictive prognostic value 62 ; however, the dynamic variability within and across different stages of disease limits the reliability of this application. 63 Plasma ctDNA analysis using single-gene testing is most valuable in the clinical resistance setting where a tissue biopsy is insufficient or unavailable and identification of the EGFR T790M mutation is required to assign thirdgeneration EGFR receptor-tyrosine kinase inhibitors (TKI). 64 A comparison of ddPCR, BEAMing PCR, ARMS-PCR and Cobas EGFR mutation test showed higher sensitivity among the digital platforms with ddPCR showing the highest concordance between plasma and tissue (74%), and BEAMing demonstrating the highest sensitivity for EGFR T790M detection (81%). The digital technologies (ddPCR and BEAMing) have invariably shown superior sensitivity for T790M detection than non-digital methods. 49 Meta-analyses comparing the diagnostic accuracy of ctDNA compared to tumour tissue for the detection of sensitizing EGFR mutations reported a pooled sensitivity and specificity of 62% and 95%, respectively. 65 Recently updated CAP/IASLC/AMP guidelines concluded that there is insufficient evidence to support the use of cfDNA for detecting sensitizing EGFR mutations upon primary diagnosis but recommend cfDNA in lieu of tissue biopsy at the time of disease progression. 25 The intermediate sensitivity (40-78%) of cfDNA for T790M detection suggests that in the event of a negative plasma T790M result, verification using tissue biopsy should be performed. Conversely, the high specificity of cfDNA equates a positive T790M result with that of a tissue biopsy and can be used to assign third-generation TKI osimertinib. 66 Currently, ctDNA testing methods in clinical use are the FDA-approved Cobas EGFR Mutation test v2 (Roche) and FoundationOne Liquid (Foundation Medicine); however, the widespread implementation of this approach in the clinic remains to be seen.
DENATURING HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY
DHPLC is an automated screening method used to identify mutations and polymorphisms in a variety of genetic diseases by detecting single base substitutions, small insertions and deletions (100-1500 bp). 67 Liquid chromatography is a column-based technique where a sample is passed through a column to separate, identify and quantify its components by measuring the absorbance and flow-through rate. 68 The method is based on separating heteroduplexes that are formed in the DNA from the process of denaturation and renaturation in a PCR. Heteroduplexes are double-stranded DNA that have mismatches between amplified chromosomal fragments due to single nucleotide insertion, deletions and substitutions. 67 DHPLC can be utilized to identify EGFR mutations in plasma and tumour tissue. 69, 70 In addition, it is inexpensive, efficient and has a high-throughput capacity. The detection limit of DHPLC is 3-10% 50 and has been reported by a number of studies to be equivalent to direct sequencing with 100% analytical sensitivity and negative predictive value with a faster turn around and lower costs. 51 Even with these benefits, it is important to understand the limitations of this method for homozygous mutations and large gene deletions (Table 4) . DHPLC only distinguishes the presence of heteroduplexes formed through mismatched alleles changing the retention time on the column, which significantly changes the elution profile compared to WT DNA. Homozygous mutations cannot be distinguished because the elution profile is very similar to the WT and cannot be differentiated. 50 
MALDI-TOF MASS SPECTROMETRY
Using the MALDI-TOF mass spectrometry and MassARRAY technology, multiplex panels such as OncoCarta, LungCarta, OncoFOCUS and UltraSEEK have been developed. 52 Other groups have developed customized panels using MALDI-TOF technology to detect for somatic mutations in NSCLC. 53 This technology is based on PCR amplification and allele-specific single-based primer extension. Each nucleotide or base added to the primer has a defined mass and is analysed using MALDI-TOF where the time of flight is proportional to the mass and is linked to specific genotype calls. 71 The actionable mutations BRAF, EGFR, KRAS, NRAS and c-Kit genes are covered by the OncoCarta Panel. Other panels include LungCarta, OncoFOCUS and the UltraSEEK. Each panel has different gene coverage and sensitivity.
Using the OncoCarta and LungFusion panels of somatic mutation and fusion genes, we recently reported mutations including EGFR, KRAS, BRAF and NRAS and gene rearrangements involving ALK, RET and ROS1 that were detected in 46.8% of patients with NSCLC. 72 The advantage of the MALDI-TOF and MassARRAY technology is the robustness of the process, especially when the sample available is small due to biopsy, after routine diagnostic IHC testing or poor quality of tumour cells. These panels are not used clinically but are commercially available for research use to detect the expanding number of therapeutically targetable mutations in lung cancer.
NEXT-GENERATION SEQUENCING
NGS is a technology that provides sequence data of all nucleotides up to a genome-wide level in input DNA or RNA in a cost-and time-efficient manner. Single nucleotide variations, amplifications or losses of chromosomal fragments, structural variations such as translocations and inversions of chromosomal regions, gene expression differences and many other alterations throughout the genome can be assessed by NGS. 73 In lung cancer, NGS has been utilized to characterize the scale and type of differences that occur in the tumour and its microenvironment. The genome-wide view enabled by NGS has also revealed characteristic 'DNA signatures' that provide evidence and insight into mechanisms of carcinogenesis. More recently, NGS enabled recognition of a 'tumour mutation burden' (TMB) phenotype, 74 characterized by excessive amounts of alterations throughout the genome. 75 Emerging reports have suggested TMB may be a promising indicator of response to immune checkpoint inhibitors, independent of PD-L1 IHC status. 76 Initially, TMB was identified from whole-exome sequencing, 74, 77, 78 but TMB derived from large gene panels 79, 80 has recently been reported to also have predictive potential. Confirmation of these associations are eagerly awaited from ongoing prospective clinical trials, while a need to streamline and harmonize the processes, mutations and thresholds used to define TMB looms on the horizon.
The capability of NGS to assess all known alterations from a single sample in a single iteration is advantageous in terms of time, cost and sample efficiency. This is opposed to current methods that consume limited tumour sample for analysis of different alterations in multiple iterations requiring varied instrumentation. Moreover, the accuracy of NGS has been shown to be superior to conventional approaches in most cases, approaching 100% when performed appropriately. Currently, a range of NGS options exists including exomeor transcriptome-specific sequencing, medium to large targeted panels with additional exploratory targets, for assessing the whole genome. 81, 82 Plasma-based NGS testing has also become available and utilized. 83 Studies have supported that these assays of tumour-derived DNA in circulation can provide a suitable representation of tumour characteristics. 84, 85 The less invasive nature of the assay has opened up the possibility for disease and treatment monitoring through longitudinal sampling, and even screening for risk prediction. 81 Further technological innovation, including pre-analytical improvements, higher depths in sequencing, adapter and bioinformatics modifications to enhance signal to noise, have paved the way for this exciting prospect.
CONCLUSION
The modern management of advanced lung cancer requires molecular testing of actionable variants to identify patients who will benefit from targeted therapeutics. Each clinical testing laboratory has unique circumstances and the adoption of a specific technology may be regulated by many factors including instrumentation and funding availability, expertise, testing purpose and specimen types. IHC is a sensitive and cost-effective method for identification of ALK rearrangements and for ROS1 screening (with subsequent validation using FISH or a molecular method). A multitude of complementary diagnostic PD-L1 IHC assays have been developed by pharmaceutical companies; however, Dako 22C3 is the only FDA-approved assay for the selection of patients for immune checkpoint inhibitors. Using data from whole-exome or targeted NGS panels, TMB is emerging as a promising predictive biomarker for immunotherapy and warrants further investigation. Despite the expense and complexity of NGS, the multiplexing throughput and high allele sensitivity allow for unmatched gene coverage. The College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) recommend the use of multigene NGS panels to reduce the need for repeat biopsy and to expand clinical trial inclusion for patients with less common but targetable mutations. 25 Where an NGS platform is unavailable, single-gene testing using real-time PCR offers a cost-effective and efficient binary outcome to guide therapy. Plasma ctDNA analysis using digital PCR or NGS platforms may be a valuable option for patients in lieu of repeat biopsy where tissue is inaccessible or insufficient. However, due to dynamic variability across different stages of disease and intermediate sensitivity, plasma genotyping for actionable biomarkers is currently recommended only upon clinical progression in advanced disease to assign third-generation TKI. Further enhancements in genomic technologies to reduce the false negative rate of ctDNA analyses may further its popularity for clinical use.
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